🚨We’re delighted to share that more than 1,000 people have now joined the FAST-Forward Boost trial, the UK's largest-ever #BreastCancer radiotherapy study.
The Institute of Cancer Research
@icr.ac.uk
The ICR is making the discoveries that defeat cancer. We're a top UK academic research centre, a postgrad college, and a charity. 📍 London (Chelsea and Sutton) https://www.icr.ac.uk/
🚨A major study has identified potential new treatment targets for the most common type of #BowelCancer. Researchers at the ICR and Royal College of Surgeons in Ireland (RCSI) used #AI to analyse the data from 2,000 patient tumour samples, identifying new vulnerabilities.
We're funding 2 new research projects using AI to predict breast cancer coming back. Find out more about our new researchers 👇 breastcancernow.org/about-us/res...
We're pleased to share that ICR's Dr @maggiecheang.bsky.social and Professor Luca Magnani have secured funding from @breastcancernow.bsky.social to uncover why some ER positive breast cancers can reappear many years after treatment.
🧬 Scientists have discovered 18 previously unknown bacterial species in DNA samples from people with #ProstateCancer.
⏰Watch Professor Uwe Oelfke's lecture on the challenges and opportunities in #radiotherapy research live at 11:30am (UK) on YouTube ⤵️ @iop.org #CancerResearch #Oncology #Science #MedSky #MedicalResearch
The Institute of Cancer Research@icr.ac.uk · 3w ago📢 Coming up on Thursday 15 October at 11:30am (UK), Professor Uwe Oelfke will give the Indian Physics Association @iop.org Cockcroft Walton Lecture from NISER Bhubaneswar in India. He'll speak about his #Radiotherapy research. You can watch it live on YouTube ⤵️ www.youtube.com/live/J-aEA9d...
Discovery comes first. Impact follows. Following his keynote at @cancer52org.bsky.social's Big Conversation, our Chief Executive, Professor Kristian Helin (@helink.bsky.social), blogs about the importance of #DiscoveryScience in defeating rare and less common cancers. www.icr.ac.uk/research-and...
Why discovery science matters for rare and less common cancers
Why discovery science matters for rare and less common cancers
icr.ac.uk
📢 Coming up on Thursday 15 October at 11:30am (UK), Professor Uwe Oelfke will give the Indian Physics Association @iop.org Cockcroft Walton Lecture from NISER Bhubaneswar in India. He'll speak about his #Radiotherapy research. You can watch it live on YouTube ⤵️ www.youtube.com/live/J-aEA9d...
IPA–IoP Cockcroft-Walton Lecture by Prof. Uwe Oelfke
YouTube video by NISER
youtube.com
Cancer cells grow fast. But that comes at a cost. Rapid growth puts huge stress on systems inside cancer cells. And if that pressure builds too much, the cancer cells can become damaged or die.
Congratulations to our poster prize winners at our Cancer Grand Challenges Conference: Spatial biology! 🎉 Soham Mandal, @icr.ac.uk, won the @natrevcancer.nature.com prize. Emine Kazanc, @icr.ac.uk, won the @aacrjournals.bsky.social #CancerDiscovery prize. A huge thank you to both journals.
What have been the biggest breakthroughs in cancer research over the past 25 years? Professor Paul Workman OBE shares his perspective in Nature Reviews Cancer's special anniversary Viewpoint on the path from cancer genomics to precision medicine. Read the article ⤵️ www.nature.com/articles/s41...
New results from the UK-led OPTIMUM (MUKnine) trial show that patients with high-risk multiple #myeloma can live significantly longer when treatment is tailored to their disease.
How do cancers regulate endoplasmic reticulum pH and stress? We show that the Golgi anion channel GPR89 plays a key role by translocating to the ER. GPR89 enhances mammary tumorigenesis and targeting GPR89 inhibits mammary cancers. Work led by the amazing Rico Ferro www.nature.com/articles/s41...
The anion channel GPR89 is a tumor-specific dependency in breast cancer - Nature Communications
Oncogene-driven endoplasmic reticulum (ER) stress is common in cancer. Here, authors show breast cancers extend Golgi anion channel GPR89 to the ER to mitigate this stress, creating a potentially targ...
nature.com
Supremely excited to share our new paper in @natcellbio.nature.com With an updated genetic cGAMP reporter, we reveal that cGAS activation by DNA damage is a rare event, and that cGAS enrichment on intracellular structures cannot be taken as evidence of activation. www.nature.com/articles/s41...
A versatile cGAMP reporter reveals principles of cGAS activation by DNA damage and chromosome instability - Nature Cell Biology
Lebrec et al. present a FRET-based cGAS reporter and show that cGAS activation by genotoxic stress is rare and uncoupled from micronuclei. The study implicates R-loop structures and subtypes of chroma...
nature.com
BREAKING 🚨: A new drug target has been discovered for an aggressive #BloodCancer. 🎥 Hear more from first author of the study, ICR's Dr Christopher Mapperley, Postdoctoral Fellow.
Very excited to announce we are looking for a software engineer to support our work developing digital pathology applications at the Integrated Pathology Unit! Check out the link below and do not hesitate to reach out if you have any questions. @icr.ac.uk #hiring jobs.icr.ac.uk/vacancies/15...
Software Engineer in Sutton | The Institute of Cancer Research
View details and apply for this Software Engineer vacancy in Sutton. Salary : Salary range: £57,190 - £64,000 per annum. Commencement on the salary range is subject to comparable skills and ...
jobs.icr.ac.uk
Using a risk assessment tool researchers at @cam.ac.uk and @icr.ac.uk have found that NICE referral criteria miss up to 95% of women under 50 who go on to develop breast cancer within 10 years. 🔗 zurl.co/6NNxS @cancerresearchuk.org @breastcancernow.bsky.social
Happy that our most recent paper on nucleotide excision repair mechanisms has now been published in Science Advances. This project was led by @natalia-mg.bsky.social and @callumhaste.bsky.social and focused on visualising early steps of the NER process by #cryoEM. www.science.org/doi/10.1126/...
Visualization of stepwise derepression of TFIIH in global genome nucleotide excision repair
Cryogenic electron microscopy captures nucleotide excision repair complexes assembling on damaged DNA templates.
science.org
🧬 25 years ago, the first draft of the human genome was published, a momentous scientific achievement opening up huge potential for drug discovery. On its anniversary, how far have we come?
We are looking for a Computational Chemist to join our Centre for Protein Degradation at the ICR @icr.ac.uk 📅 Application deadline: 31-July-2026 🔗 Learn more and apply here: jobs.icr.ac.uk/vacancies/15... #hiring #compchem #computationalchemistry #CADD #drugdiscovery #TPD #proteindegradation
Computational Chemist in Sutton | The Institute of Cancer Research
View details and apply for this Computational Chemist vacancy in Sutton. Salary : £50,825 - £53,500 per annum. Commencement on the salary range is subject to comparable skills and experience...
jobs.icr.ac.uk
🖥️ An ultrasound technology pioneered at the ICR to treat tumours without the need for surgery has successfully been adapted and used to treat a serious pregnancy condition. High intensity focused ultrasound (HIFU) uses targeted sound waves to heat and destroy cells inside the body.
📰 In our latest feature, ICR's Professor Anguraj Sadanandam explains how his pioneering research is combining #AI, advanced diagnostics and innovative preclinical models to better understand #BowelCancer and help develop more personalised treatments.
📢 New @fda.gov approval for #capivasertib in advanced #ProstateCancer. The drug, made possible by decades of research at the ICR, helps delay progression in patients with PTEN-deficient disease – an aggressive form with poor outcomes. Read more ⤵️ www.icr.ac.uk/about-us/icr...
ICR welcomes FDA approval of capivasertib for advanced prostate cancer
ICR welcomes FDA approval of capivasertib for advanced prostate cancer
icr.ac.uk
🎤 We’re delighted that ICR's Professor Paul Workman is speaking on a panel today at The Galien Foundation Forum at the @sciencemuseum.org.uk where this year’s focus is Future Health Disrupted: From Discovery to Delivery.
🎙️ICR's Professor Kevin Harrington spoke to Naga Munchetty and Chris Smith on @bbc5live.bsky.social He spoke about how the early discoveries were made that viruses could infect tumours, and how this has led to modern, genetically engineered viruses to treat cancer - called oncolytic virotherapy.
UK research shows cancer trials may be unintentionally excluding some of the patients who could benefit most. From explicit criteria like HIV status to less visible barriers like language, access isn’t always equal. Rethinking trial design is key to making research more inclusive and effective.
New findings from the OrigAMI-4, a study led by Professor Kevin Harrington in advanced head and neck cancer are presented today at #ASCO2026 ⤵️ www.asco.org/abstracts-pr...
At #ASCO2026 in Chicago, results are shared from Professor Robin Jones's study which explores a new drug for advanced GIST and how patients respond.
Also this morning at #ASCO2026, Professor James Larkin is presenting his findings from the RAMPART trial, a phase 3 study comparing durvalumab monotherapy with active monitoring after #KidneyCancer surgery ⬇️ www.asco.org/abstracts-pr...
We're delighted to have researchers from the ICR and The Royal Marsden participating in #ASCO2026 in Chicago. First up today, @prof-nick-james.bsky.social shares findings from the RAD-IO trial, a multi-stage study in #BladderCancer.
